{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:23:12Z","timestamp":1780100592085,"version":"3.54.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,17]]},"DOI":"10.7759\/cureus.33892","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T19:31:41Z","timestamp":1673983901000},"source":"Crossref","is-referenced-by-count":2,"title":["Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus"],"prefix":"10.7759","author":[{"given":"Sukhjinder","family":"Chauhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AndreyI","family":"Manov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gundip S","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinak","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Adult Diabetic Ketoacidosis","author":"Lizzo JM","year":"2022","unstructured":"Lizzo JM, Goyal A, Gupta V. Adult Diabetic Ketoacidosis. StatPearls Publishing [Internet], Treasure Island (FL); 2022."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2019-0284","article-title":"Diabetic ketoacidosis: update on management","volume":"19","author":"Evans K","year":"2019","unstructured":"Evans K. Diabetic ketoacidosis: update on management. Clin Med (Lond). 2019, 19:396-8. 10.7861\/clinmed.2019-0284","journal-title":"Clin Med (Lond)"},{"key":"ref3","article-title":"Euglycemic Diabetic Ketoacidosis","author":"Plewa MC","year":"2022","unstructured":"Plewa MC, Bryant M, King-Thiele R. Euglycemic Diabetic Ketoacidosis. StatPearls Publishing [Internet], Treasure Island (FL); 2022."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v12.i5.514","article-title":"Euglycemic diabetic ketoacidosis: a missed diagnosis","volume":"12","author":"Nasa P","year":"2021","unstructured":"Nasa P, Chaudhary S, Shrivastava PK, Singh A. Euglycemic diabetic ketoacidosis: a missed diagnosis. World J Diabetes. 2021, 12:514-23. 10.4239\/wjd.v12.i5.514","journal-title":"World J Diabetes"},{"key":"ref5","article-title":"Sodium-Glucose Transport Protein 2 (SGLT2 Inhibitors","author":"Padda IS","year":"2022","unstructured":"Padda IS, Mahtani AU, Parmar M. Sodium-Glucose Transport Protein 2 (SGLT2 Inhibitors. StatPearls Publishing [Internet], Treasure Island (FL); 2022."},{"key":"ref6","article-title":"Atypical euglycemic ketoacidosis in a non-diabetic patient due to acute pancreatitis","volume":"11","author":"Manov AE","year":"2021","unstructured":"Manov AE, Ogbu I. Atypical euglycemic ketoacidosis in a non-diabetic patient due to acute pancreatitis. World Journal of Advanced Research and Reviews. 2021, 11:332-6.","journal-title":"World Journal of Advanced Research and Reviews"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S212003","article-title":"Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician's guide","volume":"12","author":"Simes BC","year":"2019","unstructured":"Simes BC, MacGregor GG. Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician's guide. Diabetes Metab Syndr Obes. 2019, 12:2125-36. 10.2147\/DMSO.S212003","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.083","article-title":"Individualizing revascularization strategy for diabetic patients with multivessel coronary disease","volume":"74","author":"Qintar M","year":"2019","unstructured":"Qintar M, Humphries KH, Park JE, et al.. Individualizing revascularization strategy for diabetic patients with multivessel coronary disease. J Am Coll Cardiol. 2019, 74:2074-84. 10.1016\/j.jacc.2019.07.083","journal-title":"J Am Coll Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2014.11.002","article-title":"2014 ACC\/AHA\/AATS\/PCNA\/SCAI\/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons","volume":"149","author":"Fihn SD","year":"2015","unstructured":"Fihn SD, Blankenship JC, Alexander KP, et al.. 2014 ACC\/AHA\/AATS\/PCNA\/SCAI\/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Thorac Cardiovasc Surg. 2015, 149:e5-23. 10.1016\/j.jtcvs.2014.11.002","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4644-9","article-title":"Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME\u00ae randomised trial","volume":"61","author":"Verma S","year":"2018","unstructured":"Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME\u00ae randomised trial. Diabetologia. 2018, 61:1712-23. 10.1007\/s00125-018-4644-9","journal-title":"Diabetologia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen I","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015, 38:420-8. 10.2337\/dc14-1096","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease","volume":"22","author":"Bailey CJ","year":"2022","unstructured":"Bailey CJ, Day C, Bellary S. Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 2022, 22:39-52. 10.1007\/s11892-021-01442-z","journal-title":"Curr Diab Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations","volume":"7","author":"Yau K","year":"2022","unstructured":"Yau K, Dharia A, Alrowiyti I, Cherney DZ. Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep. 2022, 7:1463-76. 10.1016\/j.ekir.2022.04.094","journal-title":"Kidney Int Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_644_21","article-title":"Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis","volume":"11","author":"Dutta S","year":"2022","unstructured":"Dutta S, Kumar T, Singh S, Ambwani S, Charan J, Varthya SB. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis. J Family Med Prim Care. 2022, 11:927-40. 10.4103\/jfmpc.jfmpc_644_21","journal-title":"J Family Med Prim Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr1506573","article-title":"Type 2 diabetes, SGLT2 inhibitors, and glucose secretion","volume":"373","author":"Hattersley AT","year":"2015","unstructured":"Hattersley AT, Thorens B. Type 2 diabetes, SGLT2 inhibitors, and glucose secretion. N Engl J Med. 2015, 373:974-6. 10.1056\/NEJMcibr1506573","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4384","article-title":"Euglycemic diabetic ketoacidosis in the setting of SGLT2 inhibitor use and hypertriglyceridemia: a case report and review of literature","volume":"11","author":"Gajjar K","year":"2019","unstructured":"Gajjar K, Luthra P. Euglycemic diabetic ketoacidosis in the setting of SGLT2 inhibitor use and hypertriglyceridemia: a case report and review of literature. Cureus. 2019, 11:e4384. 10.7759\/cureus.4384","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg RM","year":"2016","unstructured":"Goldenberg RM, Berard LD, Cheng AY, Gilbert JD, Verma S, Woo VC, Yale JF. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016, 38:2654-2664.e1. 10.1016\/j.clinthera.2016.11.002","journal-title":"Clin Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-17-0081","article-title":"Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma","volume":"2017","author":"Rawla P","year":"2017","unstructured":"Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. Endocrinol Diabetes Metab Case Rep. 2017, 2017:10.1530\/EDM-17-0081","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2174\/1573399816666200316112709","article-title":"A case report: euglycemic diabetic ketoacidosis presenting as chest pain in a patient on a low carbohydrate diet","volume":"17","author":"Dorcely B","year":"2021","unstructured":"Dorcely B, Nitis J, Schwartzbard A, Newman JD, Goldberg IJ, Sum M. A case report: euglycemic diabetic ketoacidosis presenting as chest pain in a patient on a low carbohydrate diet. Curr Diabetes Rev. 2021, 17:243-6. 10.2174\/1573399816666200316112709","journal-title":"Curr Diabetes Rev"},{"key":"ref20","article-title":"Drug induced euglycemic diabetic ketoacidosis","volume":"23","author":"Badiee G","year":"2019","unstructured":"Badiee G, Lazarus ME. Drug induced euglycemic diabetic ketoacidosis. Proceedings of UCLA Health. 2019, 23:","journal-title":"Proceedings of UCLA Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/130429-empagliflozin-associated-euglycemic-diabetic-ketoacidosis-in-a-patient-with-type-2-diabetes-mellitus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:47:59Z","timestamp":1707508079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/130429-empagliflozin-associated-euglycemic-diabetic-ketoacidosis-in-a-patient-with-type-2-diabetes-mellitus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.33892","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,17]]}}}